Introduction Type 2 diabetes (T2D) is one of the major health concerns affecting 9% of the global population, putting those affected at risk of cardiovascular-associated mortality ( The incretins glucagon-like peptide-1 (GLP-1) and glucose-stimulated insulinotropic polypeptide (GIP) are peptide hormones secreted from intestinal enteroendocrine cells ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
By keeping food in the stomach longer, these medications help you feel satisfied with smaller portions, which often leads to sustainable weight loss
Wegovy for weight management) Tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist Most of these agents are administered via subcutaneous injection, with dosing frequencies ranging from twice daily to once weekly depending on the specific formulation
Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimers disease and diabetes
